Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026)
Xilio Therapeutics (XLO) posted Asset Utilization Ratio of 0.34 for Q1 2026, up 10.76% sequentially from 0.3 in Q4 2025, and up 216.82% YoY from 0.11 in Q1 2025.
Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Xilio Therapeutics has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.34 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 216.82% year-over-year to 0.34 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.34 (up 216.82% YoY) and the FY2025 annual result came in at 0.39, up 303.37% from the prior year.
- Asset Utilization Ratio improved to 0.34 in Q1 2026 per XLO's latest filing, from 0.3 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.34 in Q1 2026 and troughed at 0.11 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.40 |
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.30 |
| Sep 30, 2025 | 0.24 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.11 |